Literature DB >> 32245742

Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.

Joseph Mikhael1, Kimberly R Noonan2, Beth Faiman3, Charise Gleason4, Ajay K Nooka4, Luciano J Costa5, Sundar Jagannath6, Paul G Richardson2, David Siegel7, Ajai Chari6, Suzanne Lentzch8.   

Abstract

Entities:  

Keywords:  Adherence; Refractory multiple myeloma; Side effect management; Supportive care; Symptom management

Mesh：

Substances：

Year:  2020        PMID： 32245742     DOI： 10.1016/j.clml.2019.12.026

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN： 2152-2669


× No keyword cloud information.
  6 in total

1.  Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma.

Authors:  Cristina Gasparetto; Suzanne Lentzsch; Gary Schiller; Natalie Callander; Sascha Tuchman; Christine Chen; Darrell White; Rami Kotb; Heather Sutherland; Michael Sebag; Muhamed Baljevic; William Bensinger; Richard LeBlanc; Chris Venner; Nizar Bahlis; Adriana Rossi; Noa Biran; Heidi Sheehan; Jean-Richard Saint-Martin; Dane Van Domelen; Kazuharu Kai; Jatin Shah; Sharon Shacham; Michael Kauffman; Brea Lipe
Journal:  EJHaem       Date:  2020-11-08

2.  Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin Lymphoma: Results of a Phase I Study.

Authors:  Erlene K Seymour; Husain Yar Khan; Yiwei Li; Mahmoud Chaker; Irfana Muqbil; Amro Aboukameel; Radhakrishanan Ramchandren; Christiane Houde; Golbon Sterbis; Jay Yang; Divaya Bhutani; Silvana Pregja; Kathy Reichel; Amy Huddlestun; Colleen Neveux; Kelly Corona; Yosef Landesman; Jatin Shah; Michael Kauffman; Sharon Shacham; Ramzi M Mohammad; Asfar S Azmi; Jeffrey A Zonder
Journal:  Clin Cancer Res       Date:  2021-03-30       Impact factor: 12.531

3.  Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients.

Authors:  Michel Delforge; Jolien Raddoux; Corine Antonis; Céline Clement; Nicolas Kint; Anneleen Vanhellemont; Julie Bravetti; Peter Vandenberghe
Journal:  Onco Targets Ther       Date:  2022-03-14       Impact factor: 4.147

4.  A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation.

Authors:  Michael Cass; Andrew B McDonald; Osnat Ben-Shahar; Yosef Landesman; Trinayan Kashyap
Journal:  Am J Case Rep       Date:  2022-04-21

5.  Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series.

Authors:  Guillermina Remaggi; Paola A Ochoa; Gonzalo M Garate
Journal:  Am J Case Rep       Date:  2022-07-14

6.  A Focus on Special Populations in Relapsed Multiple Myeloma.

Authors:  Mary Steinbach; Kathleen Colson; Beth Faiman
Journal:  J Adv Pract Oncol       Date:  2022-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.